ProCE Banner Activity

Clinical Impact of New Data From CROI 2020

Slideset Download
Conference Coverage
In this downloadable slideset, CCO’s expert faculty members summarize key studies from this important annual conference, including new data on the following hot topics: late-phase investigational ART strategies, weight gain and metabolic outcomes during ART, outcomes with ART during pregnancy, rapid ART initiation, and others.

Released: March 31, 2020

Share

Faculty

Princy N. Kumar

Princy N. Kumar, MD

Professor of Medicine and Microbiology
Division of Infectious Diseases
Georgetown University Hospital
Division Chief
Division of Infectious Diseases and Travel Medicine
Department of Internal Medicine
Medstar Georgetown University Hospital
Washington, DC

Daniel R. Kuritzkes

Daniel R. Kuritzkes, 医学博士

科长,传染病科
布莱根妇女医院
Harriet Ryan Albee 医学教授
哈佛医学院
波士顿,马萨诸塞州

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Gilead

Merck & Co., Inc.

ViiV Healthcare

Faculty Disclosure

Primary Author

Princy N. Kumar, MD

Professor of Medicine and Microbiology
Division of Infectious Diseases
Georgetown University Hospital
Division Chief
Division of Infectious Diseases and Travel Medicine
Department of Internal Medicine
Medstar Georgetown University Hospital
Washington, DC

Princy N. Kumar, MD, FIDSA, MACP, has disclosed that she has served on an advisory board or panel for Amgen, Gilead Sciences, GlaxoSmithKline, Merck, and Theratechnologies; has received funds for research support from Gilead Sciences, GlaxoSmithKline, and Merck; and has ownership interest in Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, and Pfizer.

Daniel R. Kuritzkes, 医学博士

科长,传染病科
布莱根妇女医院
Harriet Ryan Albee 医学教授
哈佛医学院
波士顿,马萨诸塞州

Daniel R. Kuritzkes, MD, has disclosed that he has received consulting fees from Gilead Sciences, GlaxoSmithKline, Merck, and ViiV and funds for research support from Gilead Sciences, Merck, and ViiV.